Stephen Hart obtained his PhD in Microbiology from the University of Cape Town in 1991 then undertook a postdoc at St. Mary’s Biochemistry and Molecular Genetics Department before joining the UCL Great Ormond Street Institute of Child Health (ICH) as a postdoc then Lecturer. He was promoted to professor in 2012 and is currently Deputy Head of the Genetics and Genomic Medicines Department at ICH. He has worked in the field of genetic therapies for more than 20 years with a particular focus on non-viral therapies and has more than 100 publications to his name. His current research activities include the development of RNA and gene editing therapies, for the treatment of cystic fibrosis, primary ciliary dyskinesias and neuroblastoma. His group have developed novel synthetic nanoparticles for the delivery of nucleic acid therapeutics including siRNA, messenger RNA and CRISPR/Cas9 formulations. He is the lead investigator on a Strategic Research Centre grant funded by the Cystic Fibrosis Trust, developing CRISPR gene editing therapies for cystic fibrosis. In 2017 Stephen was elected to the board of directors of the American Society of Gene and Cell Therapy. He is a Senior Editor for the journal Annals of Human Genetics, a member of the editorial board for the journals Gene Therapy and Genes. He is the named inventor on nine patents concerning nanoparticle delivery formulations and in 2011 raised financial investment to form Nanogenic Solutions Ltd, a UCL spin-out company, commercialising nanoparticle delivery formulations for genetic therapies. He has acted as a consultant to biotech companies including Ryboquin Ltd, Glaxo SmithKline and Sanofi.